Advertisement

Medical Oncology

, 32:70 | Cite as

Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial

  • Luying Liu
  • Caineng Cao
  • Yuan ZhuEmail author
  • Dechuan Li
  • Haiyang Feng
  • Jialin Luo
  • Zhongzhu Tang
  • Peng Liu
  • Ke Lu
  • Haixing Ju
  • Na Zhang
Original Paper

Abstract

The aim of this study was to report long-term results of patients with locally advanced rectal cancer treated by neoadjuvant chemoradiotherapy with fluorouracil, leucovorin, and oxaliplatin. From February 2002 to November 2006, a total of 58 patients with locally advanced rectal cancer were recruited. Secondary endpoints included the cumulative incidence of local and distant recurrences, disease-free survival, and overall survival. The median follow-up time was 138 months (109–151 months). The cumulative incidence of local recurrence at 10 years was 12.1 %. The cumulative incidence of distant recurrence at 10 years was 53.4 %. The overall survival in the intention-to-treat population was 39.5 % at 10 years. Disease-free survival in the intention-to-treat population was 41.8 % at 10 years. Univariate analysis revealed that pathologic complete response was associated with local recurrence, distant recurrence, disease-free survival, and overall survival (p < .05). Distant recurrence remains the predominant pattern of failure for patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision. Pathologic complete response is an independent prognostic factor for locally advanced rectal cancer after preoperative chemoradiotherapy.

Keywords

Preoperative chemoradiotherapy Rectal cancer Oxaliplatin Pathologic complete response 

Notes

Acknowledgments

The present study was supported by Zhejiang Province Medical and Health Science and Technology Project (2005B011).

Conflict of interest

All authors declared no conflicts of interest.

References

  1. 1.
    Siegel R, Desantis C, Jemal A. Colorectal cancer statistics 2014. Cancer J Clin. 2014;64:104–17.CrossRefGoogle Scholar
  2. 2.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.CrossRefPubMedGoogle Scholar
  5. 5.
    André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–74.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu LY, Zhu Y, Wu L, et al. A phase study of preoperative concurrent chemoradiotherapy of oxaliplatin containing regimen for locally advanced rectal cancer. Chin J Radiat Oncol. 2007;16:286–9.Google Scholar
  9. 9.
    Simon R. Optimal two-stage designs for phase II clinical trials. Controll Clin Trials. 1989;10:1–10.CrossRefGoogle Scholar
  10. 10.
    Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Allegra JC, Yothers G, O’Connell MJ, et al. Neoadjuvant therapy for rectal cancer: mature results from NSABP protocol R-04. Gastrointestinal Cancers Symposium. J Clin Oncol. 2014; 32:abstract390.Google Scholar
  12. 12.
    Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Rodel C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial. ASCO Annual Meeting. J Clin Oncol. 2014;32:abstract3500.Google Scholar
  14. 14.
    Schmoll H, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. ASCO Annual Meeting. J Clin Oncol. 2014;32:abstract3501.Google Scholar
  15. 15.
    Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Bosset JF, Calais G, Mineur L, et al. Fluorouracil based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointest Oncol. 2014;5(5):362–73.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Mohiuddin M, Winter K, Mitchell E, Radiation Therapy Oncology Group Trial 0012, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97–102.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Garcia-Aguilar J, Marcet J, Coutsoftides T, et al. Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME. J Clin Oncol. 2011;29:abstr 3514.Google Scholar
  23. 23.
    Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys. 2008;72:644–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004;47:2025–31.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Luying Liu
    • 1
    • 2
  • Caineng Cao
    • 1
    • 2
  • Yuan Zhu
    • 1
    • 2
    Email author
  • Dechuan Li
    • 3
  • Haiyang Feng
    • 3
  • Jialin Luo
    • 1
    • 2
  • Zhongzhu Tang
    • 1
    • 2
  • Peng Liu
    • 1
    • 2
  • Ke Lu
    • 1
    • 2
  • Haixing Ju
    • 3
  • Na Zhang
    • 1
    • 2
  1. 1.Department of Radiation OncologyZhejiang Cancer HospitalHangzhouChina
  2. 2.Zhejiang Key Laboratory of Radiation OncologyHangzhouChina
  3. 3.Department of Colorectal SurgeryZhejiang Cancer HospitalHangzhouChina

Personalised recommendations